Skip to main content

Change location

You are currently on the Czech Republic (Český) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • Czech Republic (English)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • Our Foundation
    • Responsibility and Ethical conduct
  • Our Portfolio

    Proven offerings for a proven difference

    • X-ray/CT
      • Contrast agents

      • Medical devices

        • CT Exprès 3D
        • Empower CTA+
    • MRI
      • Contrast agents

        • MultiHance
        • ProHance
        • Vueway
      • Medical Devices

        • Empower MR
    • Ultrasound
      • Contrast agents

        • Sonovue
    • Nuclear medicine
    • Interventional cardiology
    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • Bracco Global Academy
    Education

    Learning, together.

    • Next-Gen Projects
    • Bracco Global Academy
    • Our Partnerships
    • Events
  • Bracco sustainability report 2024
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
Page
Cardiology Despite the availability of effective therapies, ischaemic heart disease remains the leading cause of death around the world. Early and proper diagnosis is key to reducing cardiovascular mortality and diagnostic imaging plays a crucial role here.
A surgeon preparing for surgery.
Page
Oncology According to the World Health Organization (WHO), in 2020 cancer accounted for nearly 10 million deaths worldwide – that’s almost one in every six deaths – with cancers of the lung, colon, and rectum, and prostate being the most common.
Laboratory researcher is looking through a microscope.
Article
Talking Images podcast: The sustainable way – voices of action Talking Images podcast: The sustainable way – voices of action. What do environmental sustainability and sustainable future mean?
sustainability podcast
Product
ProHance ProHance® (gadoteridol) je makrocyklická neionická molekula chelatovaná k iontu gadolinia. Má velmi nízkou osmolalitu a viskozitu. Zejména vzhledem ke své makrocyklické struktuře má ProHance® velkou stabilitu in vitro.
Bracco logo
Product
Multihance MultiHance®(dimeglumin-gadobenát) je kontrastní látka s obsahem gadolinia (GdKL) v současné době schválená v Evropské unii, v Norsku a na Islandu pro použití při vyšetření jater pomocí magnetické rezonance (MR) u dospělých a u dětských pacientů starších dvou let. 
Bracco logo
Product
Empower MR První hydraulicky poháněný injektor pro MR na světě odstraňuje potřebu baterií a s nimi související problémy. Tlakový injektor kontrastní látky EmpowerMR® je moderním systémem pro podávání kontrastních látek navrženým s cílem vyhovět požadavkům dnešních pokročilých MR postupů. EmpowerMR® lze bezpečně použit u MR se skenery 1,5 T, 3 T nebo až 7 T a jeho vývoj drží krok s rychle se měnícím oborem MR.
Bracco logo
Product
Sonovue SonoVue®, kontrastní látka pro ultrazvuková vyšetření druhé generace, je výsledkem mnohaletého výzkumu a vývoje ve společnosti Bracco. 
Bracco logo
Article
The Bracco Fellowships are back 95 grants to celebrate Bracco’s 95th Anniversary
fellowship
Article
BIPSO further strengthens environmental protection BIPSO sets the course for sterile contrast media production according to the latest environmental standards.
BIPSO production site
Article
FDA approves Gadopiclenol injection for the U.S. market Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco.
Vueway Gadopiclenol
  • Load More

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Farmakovigilance
  • VPOIS
  • Data Protection

Connect with us

Bracco Imaging Czech s.r.o.
Novodvorská 994 / 138
142 21 Praha 4
Czech Republic
VAT No CZ 24119393
+420 239 044 300

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182